These two new potential drugs are derived from replication technology effects of certain proteins, the defensins. At least forty-five laboratories and eight pharmaceutical companies working on these natural antimicrobial peptides are involved in innate immunity.

The defensins play a role in infectious diseases, but also modulate the inflammatory response and mimic the action of the body’s natural defenses. While conventional antibiotics attack the key points of the bacteria to prevent its propagation, the defensin merges with the surface of the bacterium to generate its rupture.

Dr. Beuerman, Deputy Director of SERI, explains the process: “The defensins function in a non-specific. It takes more time for bacteria to develop resistance, because it must change its entire surface. “

The challenge of SERI is to be the first to produce defensins produced by humans for these infections of the eye. The climate and the number of holders of contact lenses in the country are a breeding ground for the development of these infections.

SERI expects to test these drugs on humans within two years. If these trials are successful, placing on the market could take place within three to five years.

Related Posts:

• Three-fourth of anibiotics prescriptions would be useless
• Multiresistant bacteria to antibiotics decrypted the molecular mechanism
• Discovery of a new strategy of resistance to antibiotics
• Women have a better immune system than men
• U.S. researchers are developing a new antibacterial paint
• Cholesterol: tomato extract beats statins?
• Reconstructing the cornea with contact lenses